




RealRate

PHARMACEUTICAL 2018

Karyopharm Therapeutics Inc
Rank 175 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Karyopharm Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Karyopharm Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Karyopharm Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 36% points.

The company's Economic Capital Ratio, given in the ranking table, is 255%, being 3.4% points above the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	148,423
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	49,467
Liabilities, Non-Current	0
Other Assets	29,686
Other Compr. Net Income	57
Other Expenses	63
Other Liabilities	1,363
Other Net Income	3,222
Other Revenues	0
Property and Equipment	2,185
Research and Development	107,273
Selling, General and Administrative Expense	24,870

Output Variable	Value in 1000 USD
Assets	180,294
Liabilities	50,830
Expenses	132,206
Revenues	0
Stockholders Equity	129,464
Net Income	-128,984
Comprehensive Net Income	-128,956
BaseVar	183,304
ECR before LimitedLiability	133%
Economic Capital Ratio	255%